The supplementary materials for the article "Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy" by Isaure Vanmeerbeek et al. provide comprehensive supporting data and methods. The materials include: 1. **Figures S1 to S14**: These figures detail the analysis of HAVCR2+VSIR+ TAMs in immuno-resistant human and murine tumors, including scRNAseq data, flow cytometry results, and differential pathway enrichment analyses. 2. **Tables S1 and S2**: These tables provide detailed information on the pan-cancer immune landscape classes and the composition of TCGA datasets. 3. **Gating Strategies**: Detailed flow cytometry gating strategies are provided to ensure reproducibility and clarity in the analysis. 4. **Western Blots**: Western blots are included to validate the expression of various proteins such as HMGB1, VISTA, Galectin9, Ceacam1, and PSGL1 in different conditions. 5. **Additional Data**: The supplementary materials also include additional data on the therapeutic blockade of TIM3+VISTA+ TAMs, the induction of immunogenic cell death by chemotherapy, the pro-efferocytic nature of TIM3 and VISTA, the increase in MHCII+ macrophages, and the impact on T cell and DC subsets in suppressed tumors. These supplementary materials enhance the understanding of the mechanisms underlying the resistance to cancer immunotherapy and provide a robust foundation for further research.The supplementary materials for the article "Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy" by Isaure Vanmeerbeek et al. provide comprehensive supporting data and methods. The materials include: 1. **Figures S1 to S14**: These figures detail the analysis of HAVCR2+VSIR+ TAMs in immuno-resistant human and murine tumors, including scRNAseq data, flow cytometry results, and differential pathway enrichment analyses. 2. **Tables S1 and S2**: These tables provide detailed information on the pan-cancer immune landscape classes and the composition of TCGA datasets. 3. **Gating Strategies**: Detailed flow cytometry gating strategies are provided to ensure reproducibility and clarity in the analysis. 4. **Western Blots**: Western blots are included to validate the expression of various proteins such as HMGB1, VISTA, Galectin9, Ceacam1, and PSGL1 in different conditions. 5. **Additional Data**: The supplementary materials also include additional data on the therapeutic blockade of TIM3+VISTA+ TAMs, the induction of immunogenic cell death by chemotherapy, the pro-efferocytic nature of TIM3 and VISTA, the increase in MHCII+ macrophages, and the impact on T cell and DC subsets in suppressed tumors. These supplementary materials enhance the understanding of the mechanisms underlying the resistance to cancer immunotherapy and provide a robust foundation for further research.